Member Info for VikR

Come on FDA put us out of our misery

This deserves to be commercialized for the sake of the sufferers of pulmonary fibrosis out there. A horrible degenerative disease so any intervention to improve a patients quality of life is hugely rewarding and welcome

Buying the dip

£7k done

Will look to continue adding and stockpiling sub 0.2

Hugely undervalued and patience needs to be exercised here. There is most likely considerable sums of money to be made for us all, as lets be honest at the current price one can mop up lots of shares for every £10k you invest

Load and hold and have conviction in your research

Topped up around 20k yesterday, @1 .62p

could have got a better entry but such is life.

will continue to stake build now we have hit the month with better comms and a 3rd project

Another £7148 added

Spoke to a professional trader today and had a long conversation on share picks for 2026. He was strongly of the opinion that JAN at present is a very lucrative share to average down in. We now have a minimum of 2 gold projects to look forward to and looking how advanced Paranaita is the market simply hasn’t re rated it to anywhere near any of its peers. We also have the 100% Pitombeiras vanadium titanomagnetite project in the state of Cear.

Excited to see the next upward move on JAN

Just topped up another 10k

Time to start loading heavy again here with upcoming newsflow and a very low market cap which should be x5 on speculation alone

The marketplace is ridiculously undervaluing the fundamentals on offer here. I have noticed this theme among the shares with proven resources and assets in situ to be at a complete disconnect to their respective market cap value. To name a few

-ORR

-Rock

-UFO

Irrespective of having a skewed opinion as I am heavily invested in all 3, it can only be a matter of time until the market has to let go and let it re rate to something even closely resembling true value. I suppose it gives investors an ample timed opportunity to get in at the bottom but the upwards move is now long overdue.

Yes definitely so

Idiopathic pulmonary fibrosis is a rare condition as one will get. On top of this treatment options are limited to a handful and there is definitely no inhaled therapy, that will be a first. Asthma and COPD all rely on inhaled therapy as mainstay treatment and it looks like nuformix could be the first to revolutionize it for IPF.

I must say Dan Gooding has backed a winner here and the future looks bright albeit patience needed

The market is fickle and stupid at valuing stocks. I say that about all my investments as I am biased (haha). However the market is especially crazy about valuing Rock - the re rate is staring us in the face. How can it still be here even now is beyond comprehension.

0.5p pit stop 1

Having seen historical delays similar to this with the FDA it almost always leads to approval in my experience. According to the FDA website transilast (oral form

I imagine) has already had orphan drug designation in 2003/2010 for glioma (malignant brain cancer) and scarring post glaucoma surgery. There is no reason why repurposed inhaled transilast would fail the same classification.

Link below:

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm

Look at the major benefits of orphan drug approval:

7-Year Exclusivity: Upon approval, the drug receives 7 years of marketing exclusivity, during which the FDA generally cannot approve another application for the same drug for the same indication.

Tax Credits: Qualified clinical trial costs can be eligible for tax credits.

Fee Waivers: Exemption from user fees, such as the Prescription Drug User Fee Act (PDUFA) fee.

The market needs to wake up and acknowledge that this going to Rerate on the next RNS

I had no idea this was being worked on in the background but Paulo has always been about scaling big as per his historical appointments. I think he wants to retire after one big massive career defining moment and we are so lucky at JAN to have him on board. Now they have also reinforced Paranaita results to be obtained this month this surely needs to be in the 3p+ region based on hype and speculation alone. As usual the MMs will sporadically let it go at some unexpected time when you least expect it. This share is to difficult to trade so best to ride through the turbulence and just acquire sub2p.

Good luck to all that held through the quiet period

Nice 2 million buy this morning on there

The cumulative value of everything in the ground is mind boggling. Even if only 10% of that bears fruition we are still taking a market cap many many millions of where we currently reside.

This is an evidenced based solid as rock buy and a must have for any type of portfolio big or small looking for short term to long term MASSIVE upside gains.

Unusual price action

I haven’t sold any or added any today, I have emailed Hugo to elaborate on work streams in more detail. Still a compelling buy and it looks like it will be another rise out of the blue when the MMs decide to let it go. Should be 2-3p by now as a baseline.

Only thing I can advise is stay firm and not sell out if you are in for the long term. Day traders will probably want to cash out.

That’s an excellent narrative on the current state of play and a huge tax advantage and one that is not even baked into the price. This reaffirms my confidence even further in ECR and the meagre market cap that has been attributed to this share at present.

A sitting acquisition target for many multiples of where the share price currently sits.

As promised largest holding in my portfolio now and shares tucked away. I need one of my shares to multibag and at least 6 figures and 7 is the ultimate end goal for me. Now time to sit back and let David Price CEO micromanage at the top to a successful conclusion

This will get into the pennies this year, I am confident of that. Only a matter of time this re rates upwards. One to patiently load and leave and let ORR keep on working systematically to achieve the set objectives.

Just as I had expected Paulo is strategically drilling in the areas of highest probability and it has worked as expected. The JORC estimate is 100% to be upgraded from the current 210 oz Au, and I imagine quite significantly pending conclusion of putting all the results together.

A very positive update which is evidenced based and based on quantifiable data.

Paranaita is proving to be a world class resource and I can see this as a pathway to viable open pit mine operation in the future.

Time to load and hold sub 2p golden opportunity

And on that note also took £5k today

Welcome definitely oversold and undervalued. SVN 001 is getting out licensed this year, good as confirmed in the last interview. SVN 002 is a massive play but incremental stages to be reached with bridging study confirmation and then FDA application swiftly after for phase 2B. SVN015 hopefully gets selected for the grant. SVN-SDN-14 series gets added in for good measure.

While the SP is quiet and stagnant that’s the best time to accumulate, when it shoot’s up on deal announcement it will trigger a HUMONGOUS re rate for the ENTIRE PORTFOLIO, 100 Million MCAP minimum